Milestone Pharmaceuticals Inc. Proceeds from Issuance of Convertible Preferred Stock
Milestone Pharmaceuticals Inc. (MIST) reported Proceeds from Issuance of Convertible Preferred Stock of $138.80 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2021-05-17
- Milestone Pharmaceuticals Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2020-12-31 was $0.00.
- Milestone Pharmaceuticals Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2020-09-30 was $0.00.
- Milestone Pharmaceuticals Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2020-06-30 was $0.00.
- Milestone Pharmaceuticals Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2020-03-31 was $138.80M.
- Milestone Pharmaceuticals Inc. proceeds from issuance of convertible preferred stock for fiscal 2020 was $138.80M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 6 month | Proceeds from Issuance of Convertible Preferred Stock 9 month | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $0.00 derived: sum of 2 quarters · filed 2021-03-29 | $0.00 derived: sum of 3 quarters · filed 2021-03-29 | $138.80M 10-K · filed 2021-03-29 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $0.00 derived: sum of 2 quarters · filed 2020-11-13 | $138.80M 10-Q · filed 2020-11-13 | ||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $138.80M 10-Q · filed 2020-08-12 | |||
| 2020-03-31 | $138.80M 10-Q · filed 2020-05-14 | ||||
| 2019-04-30 | $138.80M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |